Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized monoclonal antibody 3S193 (90Y-hu3S193) in patients with advanced ovarian cancer
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2005
At a glance
- Drugs Monoclonal antibody 3S193 Y-90 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 16 Aug 2005 New trial record.